Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment

被引:7
作者
Yu, Hongjie [1 ]
Shi, Zhuqing [1 ]
Lin, Xiaoling [2 ]
Bao, Quanwa [3 ]
Jia, Haifei [2 ]
Wei, Jun [1 ]
Helfand, Brian T. [1 ]
Zheng, Siqun. L. [1 ]
Duggan, David [4 ]
Lu, Daru [3 ]
Mo, Zengnan [5 ]
Xu, Jianfeng [1 ,2 ]
机构
[1] NorthShore Univ HealthSyst, Program Personalized Canc Care, 1001 Univ Pl, Evanston, IL 60201 USA
[2] Fudan Univ, Huashan Hosp, Fudan Inst Urol, Shanghai, Peoples R China
[3] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[4] City Hope Natl Med Ctr, Translat Genom Res Inst, Phoenix, AZ USA
[5] Guangxi Med Univ, Ctr Genom & Personalized Med, Nanning, Guangxi Zhuang, Peoples R China
关键词
clinical validity; genetic risk score; prostate cancer; GENOME-WIDE ASSOCIATION; MEN; PREDICTION; VARIANTS; BIOPSY;
D O I
10.1002/pros.23920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Several polygenic risk score (PRS) methods are available for measuring the cumulative effect of multiple risk-associated single nucleotide polymorphisms (SNPs). Their performance in predicting risk at the individual level has not been well studied. Methods We compared the performance of three PRS methods for prostate cancer risk assessment in a clinical trial cohort, including genetic risk score (GRS), pruning and thresholding (P + T), and linkage disequilibrium prediction (LDpred). Performance was evaluated for score deciles (broad-sense validity) and score values (narrow-sense validity). Results A training process was required to identify the best P + T model (397 SNPs) and LDpred model (3 011 362 SNPs). In contrast, GRS was directly calculated based on 110 established risk-associated SNPs. For broad-sense validity in the testing population, higher deciles were significantly associated with higher observed risk;P(trend)was 7.40 x 10(-11), 7.64 x 10(-13), and 7.51 x 10(-10)for GRS, P + T, and LDpred, respectively. For narrow-sense validity, the calibration slope (1 is best) was 1.03, 0.77, and 0.87, and mean bias score (0 is best) was 0.09, 0.21, and 0.10 for GRS, P + T, and LDpred, respectively. Conclusions The performance of GRS was better than P + T and LDpred. Fewer and well-established SNPs of GRS also make it more feasible and interpretable for genetic testing at the individual level.
引用
收藏
页码:83 / 87
页数:5
相关论文
共 50 条
[31]   A Polygenic Risk Score Predicts Incident Prostate Cancer Risk in Older Men but Does Not Select for Clinically Significant Disease [J].
Bakshi, Andrew ;
Riaz, Moeen ;
Orchard, Suzanne G. ;
Carr, Prudence R. ;
Joshi, Amit D. ;
Cao, Yin ;
Rebello, Richard ;
Nguyen-Dumont, Tu ;
Southey, Melissa C. ;
Millar, Jeremy L. ;
Gately, Lucy ;
Gibbs, Peter ;
Ford, Leslie G. ;
Parnes, Howard L. ;
Chan, Andrew T. ;
McNeil, John J. ;
Lacaze, Paul .
CANCERS, 2021, 13 (22)
[32]   Development and Validation of a Genome-Wide Association Study Based Polygenic Risk Score for Prostate Cancer in an Asian Population [J].
Geng, Jiun-Hung ;
Yu, Chia -Cheng ;
Huang, Chao -Yuan ;
Lin, Victor C. ;
Li, Chia -Yang ;
Wu, Ming-Tsang ;
Chen, Szu-Chia ;
Bao, Bo-Ying ;
Huang, Shu-Pin .
WORLD JOURNAL OF MENS HEALTH, 2025,
[33]   Exome-based genome-wide association study and risk assessment using genetic risk score to prostate cancer in the Korean population [J].
Oh, Jong Jin ;
Lee, Soo Ji ;
Hwang, Joo-Yeon ;
Kim, Dokyoon ;
Lee, Sang Eun ;
Hong, Sung Kyu ;
Ho, Jin-Nyoung ;
Yoon, Sungroh ;
Sung, Joohon ;
Kim, Wun-Jae ;
Byun, Seok-Soo .
ONCOTARGET, 2017, 8 (27) :43934-43943
[34]   The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer [J].
Kang, Ho Won ;
Jung, Hae Do ;
Lee, Joo Yong ;
Kwon, Jong Kyou ;
Jeh, Seong Uk ;
Cho, Kang Su ;
Ham, Won Sik ;
Choi, Young Deuk .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, 33 (05)
[35]   A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer [J].
Farazi, Manzur ;
Yang, Xin ;
Gehl, Carson J. ;
Barnett, Gillian C. ;
Burnet, Neil G. ;
Chang-Claude, Jenny ;
Parker, Christopher C. ;
Dunning, Alison M. ;
Azria, David ;
Choudhury, Ananya ;
Rancati, Tiziana ;
De Ruysscher, Dirk ;
Seibold, Petra ;
Sperk, Elena ;
Talbot, Christopher J. ;
Veldeman, Liv ;
Webb, Adam J. ;
Elliott, Rebecca ;
Aguado-Barrera, Miguel E. ;
Carballo, Ana M. ;
Fuentes-Rios, Olivia ;
Gomez-Caamano, Antonio ;
Peleteiro, Paula ;
Vega, Ana ;
Ostrer, Harry ;
Rosenstein, Barry S. ;
Saito, Shiro ;
Parliament, Matthew ;
Usmani, Nawaid ;
Marples, Brian ;
Chen, Yuhchyau ;
Morrow, Gary ;
Messing, Edward ;
Janelsins, Michelle C. ;
Hall, William ;
West, Catharine M. L. ;
Auer, Paul L. ;
Kerns, Sarah L. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2025, 34 (05) :795-804
[36]   Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry [J].
Chen, Fei ;
Madduri, Ravi K. ;
Rodriguez, Alex A. ;
Darst, Burcu F. ;
Chou, Alisha ;
Sheng, Xin ;
Wang, Anqi ;
Shen, Jiayi ;
Saunders, Edward J. ;
Rhie, Suhn K. ;
Bensen, Jeannette T. f ;
Ingles, Sue A. ;
Kittles, Rick A. ;
Strom, Sara S. ;
Rybicki, Benjamin A. ;
Nemesure, Barbara ;
Isaacs, William B. ;
Stanford, Janet L. ;
Zheng, Wei ;
Sanderson, Maureen ;
John, Esther M. ;
Park, Jong Y. ;
Xu, Jianfeng ;
Wang, Ying ;
Berndt, Sonja I. ;
Huff, Chad D. ;
Yeboah, Edward D. ;
Tettey, Yao ;
Lachance, Joseph ;
Tang, Wei ;
Rentsch, Christopher T. ;
Cho, Kelly ;
Mcmahon, Benjamin H. ;
Biritwum, Richard B. ;
Adjei, Andrew A. ;
Tay, Evelyn ;
Truelove, Ann ;
Niwa, Shelley ;
Sellers, Thomas A. ;
Yamoah, Kosj ;
Murphy, Adam B. ;
Crawford, Dana C. ;
Patel, Alpa V. ;
Bush, William S. ;
Aldrich, Melinda C. ;
Cussenot, Olivier ;
Petrovics, Gyorgy ;
Cullen, Jennifer ;
Neslund-Dudas, Christine M. ;
Stern, Mariana C. .
EUROPEAN UROLOGY, 2023, 84 (01) :13-21
[37]   Economic evaluation of prostate cancer risk assessment methods: A cost-effectiveness analysis using population data [J].
Mohammadi, Tima ;
Guh, Daphne P. ;
Tam, Alexander C. T. ;
Pataky, Reka E. ;
Black, Peter C. ;
So, Alan ;
Lynd, Larry D. ;
Zhang, Wei ;
Conklin, Annalijn I. .
CANCER MEDICINE, 2023, 12 (19) :20106-20118
[38]   Inherited risk assessment of prostate cancer: it takes three to do it right [J].
Xu, Jianfeng ;
Labbate, Craig V. ;
Isaacs, William B. ;
Helfand, Brian T. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (01) :59-61
[39]   Assessment of the associations between three VEGF polymorphisms and risk of prostate cancer [J].
Chen, Guo-Qiang ;
Luo, Jian-bin ;
Wang, Guang-Zhi ;
Ding, Jin-E .
TUMOR BIOLOGY, 2014, 35 (03) :1875-1879
[40]   Prevalence and diversity of management of prostate cancer patients classified as low risk using D'Amico group or Cancer of the Prostate Risk Assessment (CAPRA) score: A French multicenter study [J].
Leon, P. ;
Cancel-Tassin, G. ;
Koutlidis, N. ;
Calves, J. ;
de la Vega, M. Funes ;
Fournier, G. ;
Valeri, A. ;
Cormier, L. ;
Larre, S. ;
Cussenot, O. .
PROGRES EN UROLOGIE, 2017, 27 (03) :158-165